Zonmox-CV 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg, designed to treat a wide range of bacterial infections. Amoxycillin, a broad-spectrum penicillin antibiotic, acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Amoxycillin by preventing the degradation of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination is effective against various infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media. Zonmox-CV 625 is indicated for use in both community-acquired and hospital-acquired infections where beta-lactamase producing organisms are suspected. The usual dosage and duration depend on the severity and site of infection, and it should be administered as prescribed by a healthcare professional. Caution is advised in patients with a history of penicillin allergy or hypersensitivity to beta-lactam antibiotics. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and rash. It is essential to complete the full course of therapy to prevent the development of resistance. Zonmox-CV 625 should be stored at room temperature, away from moisture and direct sunlight.